EE162 Cost-Effectiveness Analysis of Pembrolizumab in Combination With Enfortumab Vendotin for First-Line Treatment of Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Abstract
Authors
Nikolaos Yfantopoulos ANASTASIOS SKROUMPELOS Antonis Karokis George Emmanouil Akanksha Rai Diksha Vohra Shujing (Shirley) Zhang